Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
Princess Margaret Cancer Centre · General University Hospital in Prague · +18 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
543
total citations
- FWCI
- 30.73
- Percentile
- 100%
- References
- 33
Citations per year
Authors
19- AMAmit M. OzaCorresponding
Princess Margaret Cancer Centre
- DCDavid Cibula
General University Hospital in Prague
- AOAna Oaknin Benzaquen
Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology
- CPChristopher Poole
University Hospitals Coventry and Warwickshire NHS Trust
- RHRon H.J. Mathijssen
Erasmus MC Cancer Institute
Topics & keywords
Topics
Keywords
- Olaparib
- Medicine
- Carboplatin
- Tolerability
- Internal medicine
- Regimen
- Ovarian cancer
- Chemotherapy
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.